Key Takeaways from BIO International 2026

Capital is coming back, deal activity is picking up, and new science keeps expanding what's possible. But two structural forces - the rise of Chinese biopharma and the uncertainty around most favored nation pricing - are quietly rewriting the playbook that has served this industry for a decade.

The KYBORA Team pulled together BIO's Key Takeaways - download our white paper to explore them.

KYBORA is a global investment bank that helps Biopharma Leaders close the right strategic transactions globally. We combine deep industry judgment, trusted decision-maker relationships, senior-led execution, and financing expertise to advise on M&A, Licensing and Partnering, Capital Raising, and other high-stakes strategic situations. With offices in the US, Switzerland, and China, and a direct presence across all key biopharma markets, KYBORA brings the global reach, local insight, and credibility to move complex transactions to completion.